WO1999047486A1 - Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines - Google Patents

Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines Download PDF

Info

Publication number
WO1999047486A1
WO1999047486A1 PCT/EP1999/001696 EP9901696W WO9947486A1 WO 1999047486 A1 WO1999047486 A1 WO 1999047486A1 EP 9901696 W EP9901696 W EP 9901696W WO 9947486 A1 WO9947486 A1 WO 9947486A1
Authority
WO
WIPO (PCT)
Prior art keywords
copper
cis
compound
catalyst
imine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/001696
Other languages
English (en)
French (fr)
Inventor
Heinz Steiner
Markus Benz
Hans-Peter Jalett
Marc Thommen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Spezialitaetenchemie Holding AG
Ciba SC Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Spezialitaetenchemie Holding AG, Ciba SC Holding AG filed Critical Ciba Spezialitaetenchemie Holding AG
Priority to DE69916593T priority Critical patent/DE69916593T2/de
Priority to EP99915616A priority patent/EP1064250B1/en
Priority to US09/646,211 priority patent/US6232501B1/en
Priority to IL13817299A priority patent/IL138172A0/xx
Priority to JP2000536684A priority patent/JP2002506844A/ja
Priority to CA002323629A priority patent/CA2323629A1/en
Priority to AU34128/99A priority patent/AU759530B2/en
Publication of WO1999047486A1 publication Critical patent/WO1999047486A1/en
Priority to IL138172A priority patent/IL138172A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/44Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
    • C07C209/52Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of imines or imino-ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the present invention relates to a novel, inventive process for the cis-selective catalytic hydrogenation of cyclohexylidenamines and their precursors.
  • Cyclohexylamines can be used, inter alia, as antioxidants and as pharmaceutical active substances.
  • An important cyclohexylamine is sertraline:
  • sertaline has the 1 S-, 4S-configuration.
  • Cyclohexylamine is obtained, for example, by the following method: Reacting the ketone
  • the resultant imine is then catalytically hydrogenated to the amine. These reactions proceed without, or only with minor, stereoselectivity. In the case of sertraline, four enantiomers are obtained.
  • This invention has for its object to prepare cyclohexylamines having as high as possible a cis-isomer proportion.
  • R 2 3,4-dichlorophenyl using palladium and carbon as substrates. This affords 70 % of cis- and 30 % of trans- racemate.
  • WO 93/01161 proposes to replace palladium and carbon as substrate by Raney nickel when hydrogenating the imine. This results in a cis/trans ratio of 8:1. Surprisingly, it has now been found that an even better cis/trans ratio is obtained if the - 3 -
  • imine is catalytically hydrogenated in the presence of a copper.
  • the preparation of secondary amines from ketones and intermediate imines by hydrogenation in the presence of copper chromite catalysts is known from ft B. C. Pillai J. Mol. Catalysis 84 (1993), 125 - 129.
  • copper chromite catalysts is known from ft B. C. Pillai J. Mol. Catalysis 84 (1993), 125 - 129.
  • This invention relates to a process for the preparation of cis-compounds of formula: y
  • R, and R 2 are each independently of the other hydrocarbon radicals and A is sub- stituents, and m is an integer from 0 to 4 and defines the number of the substituents A, which process comprises a) hydrogenating a cyclohexylidenamine of formula:
  • a (m)" is used. If in a compound (I) m is 1 to 4 (m > 0) and the cyclohexyl ring is unsymmetrically substituted, then a cis-enantiomer pair is selectively obtained during hydrogenation which can be separated into the optically pure antipodes by customary methods of racemate resolution, for example by crystallisation of the mandelic acid salt by the method of W.M.Welch et al in J. Med. Chem. 1984, 27, 1508-1515. The relationship between the two cis- and trans- enantiomer pairs and the 4 optically pure antipodes is illustrated by the following formula scheme of sertraline:
  • the unbroken bonding dashes to the substituent R 2 signify that in the case of R 2 ⁇ H and of different substitution at the cyclohexyl ring, these starting materials can be used in the process in the form of racemic mixtures having identical or different antipode proportions or in the form of an optically pure antipode.
  • the process is distinguished by a high yield of the desired cis-compounds.
  • a ratio of the cis- to the trans-enantiomer pair is obtained which is higher than 95:5.
  • the even better ratio of higher than 99:1 is obtained.
  • This high cis-compound yield obviates the separation of the cis- from the trans-enantiomer pair which is otherwise necessary when different substi- tuents A (m > 0) are present.
  • a hydrocarbon radical R ⁇ , or R 2 is preferably selected from the group consisting of C C 2 o- alkyl, C 4 -C 12 cycloalkyl, C 2 -Cnheterocycloalkyl, carbocyclic C 5 -C 16 aryl, C 2 -C 15 heteroaryl, car- bocyclic C 7 -C 16 aralkyl and C 2 -C ⁇ sheteroarylalkyl and can in addition be substituted by suitable functional groups, for example by the functional groups or derivatised functional groups consisting of amino, CrC ⁇ lkyiamino, CrC ⁇ dialkylamino, hydroxy, carboxy and halogen.
  • the cyclohexyl ring can be substituted by 1 to 4, preferably by 2, substituents from the group A containing the substituents R 3 , R 4 , R 5 and R 6 .
  • Suitable substituents are listed in the List of Radical Names, valid according to IUPAC Rules, and remain unchanged under the conditions of the catalytic hydrogenation reaction. Any of the substituents may be chosen.
  • Suitable substituents A from the group R 3 , R 4 , R 5 and R 6 are selected, for example, from the group of the functional groups or derivatised functional groups consisting of amino, CrC 4 - alkylamino, d-Cdialkylamino, hydroxy, carboxy and halogen, or are saturated or unsatura- ted aliphatic, cycloaiiphatic or heterocycloaliphatic radicals, carbocyclic or heterocyclic aryl radicals, condensed carbocyclic, heterocyclic or carbocyclic-heterocyclic radicals, which can in turn be combined with any others of these radicals and which can be substituted by the cited functional groups or derivatised functional groups.
  • two substituents A from the group R 3 , R 4 , R 5 and R 6 are bivalent, bridge-like C 2 -C 6 alkylene, C 4 -C 8 alkyldiylidene or C 4 -C 8 alkenyldiylidene groups, preferably butanediyiidene, more preferably 2-butenediylidene, which is bound with the cyclohexyl ring to two adjacent carbon atoms and which forms together with these car- - 6 -
  • Suitable substituents A from the group R 3 , R 4 , R 5 and R 6 are also substituents from the group CrC 20 alkyl, C 4 -C 12 cycloalkyl, C 7 -C 12 bicycloalkyl, C 2 -Cnheterocycloalkyl, carbocyclic C 6 -C 16 aryl, C 2 -C ⁇ 5 heteroaryl, carbocyclic C 7 -C 16 aralkyl and C 2 -C 15 heteroarylalkyl, which can in turn be substituted by the cited functional groups and interrupted by bivalent radicals.
  • C C 20 Alkyl is, for example, methyl, ethyl, n- or isopropyl or n-, sec- or tert-butyl and straight- chain or branched pentyl, hexyl, heptyl, octyl, isooctyl, nonyl, tert-nonyl, decyl, undecyl or dodecyl.
  • Cycloalkyl is, for example, cyclopropyl, dimethylcyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • C 7 -C 12 Bicycloalkyl is, for example, bornyl or norbornyl.
  • C 2 -CnHeterocycloalkyl preferably contains 4 or 5 carbon atoms and one or two heteroatoms from the group O, S and N.
  • Examples are the substituents derived from oxirane, azirine, 1 ,2- oxathiolane, pyrazoline, pyrrolidine, piperidine, piperazine, morpholine, tetrahydrofuran or tetrahydrothiophene.
  • Carbocyclic C 6 -C 16 aryl is, for example, mono-, bi- or tricyclic, typically phenyl, naphthyl, in- denyl, azulenyl or anthryl.
  • Heteroaryl is preferably monocyclic or is condensed with a further heterocycle or with an aryl radical, for example phenyl, and preferably contains one or two, in the case of nitrogen up to four, heteroatoms from the group O, S and N.
  • Suitable substituents are derived from furan, thiophene, pyrrole, pyridine, bipyridine, picoline, ⁇ -pyran, ⁇ -thiopyran, phenan- throline, pyrimidine, bipyrimidine, pyrazine, indole, coumarone, thionaphthene, carbazole, di- benzofuran, dibenzothiophene, pyrazole, imidazole, benzimidazole, oxazole, thiazole, dithi- azole, isoxazole, isothiazole, quinoline, isoquinoline, acridine, chromene, phenazine, phen- oxazine, phenothiazine, triazine, thianthrene, purine or tetrazole.
  • Carbocyclic CrC ⁇ aralkyl preferably contains 7 to 12 carbon atoms, e.g. benzyl, 1- or 2- phenethyl or cinnamyl.
  • Heteroarylalkyl preferably consists of the cited heterocycles, which substitute e.g. C C 4 alkyl radicals, depending on the length of the carbon chain where possible terminally, or else also in adjacent position (1 -position) or in ⁇ -position (2-position).
  • R ⁇ is C C 4 alkyl and R is aryl.
  • R ⁇ and R 2 have the cited meanings, which imine or ketone may be in syn- or anti- form, is hydrogenated in the presence of a copper-containing catalyst.
  • ketone (III) preferably a ketone of formula
  • R 2 has the cited meanings, is reacted with a compound introducing the R r N-)(0) n group, in particular with a primary amine, preferably methylamine, or with a R substituted hydroxylamine, preferably N-methylhydroxylamine, and the imine (II) which is obtainable as intermediate is hydrogenated in situ in the presence of a copper-containing catalyst. It is also possible to replace the racemic compound (IT) or (III') with an optically pure compound (IT) or (III') and to react it to a cis-compound (I').
  • This invention preferably relates to a process for the preparation of the cis-compound (I'), wherein R, is methyl and R 2 is 3,4-dichiorophenyl, which process comprises - 8 -
  • Suitable catalysts for the hydrogenation reaction according to variants a) and b) are copper- containing catalysts, for example copper skeleton, copper substrate, copper chromite, copper zinc oxide, copper boride or copper urushibara catalysts.
  • other elements are present in the catalyst besides copper.
  • elements are aluminium, chromium, zinc, barium, manganese, zirconium, vanadium, molybdenum, titanium, tantalum, niobium, tungsten, nickel, cobalt, bismuth, tin, antimonium, hafnium, rhenium, iron, cadmium, lead or germanium and mixtures thereof.
  • the amount in which the element is added can vary within wide limits and may be from 10 ppm to 200% in relation to the amount of copper used.
  • Particularly suitable elements are aluminium, zinc, chromium, barium and manganese.
  • the elements can be, for example, in the form of oxides or salts, such as chromates.
  • Raney copper is an example of a suitable copper skeleton catalyst.
  • substrates are carbon, aluminium oxide, silicium dioxide, Cr 2 0 3 , zirconium dioxide, zinc oxide, calcium oxide, magnesium oxide, barium sulfate, calcium carbonate or aluminium phosphate.
  • the copper can be bound on the substrate in an amount of about 1.0 - 20.0 % by weight.
  • a suitable copper chromite catalyst is represented by the empirical formula CuO*CuCr 2 0 4 .
  • CuCr 2 0 4 is known, see C.A.R.N. 12018-10-9 and Gmelins Handbuch der Anorganischen Chemie, 8 th ed., Vol. Kupfer, part B, instalment 3, system number 60, page 60.
  • a common name is also copper(ll)chromate(lll).
  • Copper chromite catalysts having changing proportions of CuO and CuCr 2 0 4 , Raney copper catalysts and copper-zinc-aluminium-oxide catalysts are commercially available in pure form or in a form doped with the cited elements.
  • the copper-containing catalysts used are copper chromite catalysts or catalysts containing copper, zinc and aluminium in the form of oxides.
  • the cited catalysts are present in the reaction mixture in an amount of about 0.1 to 100 % by weight, preferably of 1 -20 % by weight, based on the amount of educt used.
  • the copper-containing catalysts can be used in different ways in the process:
  • catalysts prepared in situ from suitable precursors, such as copper salts or oxides, and from other compounds.
  • prehydrogenation it is possible to treat e.g. a suspension of the catalyst in a suitable solvent under 5 to 150 bar hydrogen at 80-250°C for half an hour to 5 hours, or hydrogen is introduced under normal pressure up to 50 bar at 100 to 500°C over the dry catalyst.
  • the catalyst used is activated by hydrogenation in the solvent which is used for hydrogenating the imine or nitrone ("prehydrogenation").
  • the catalyst can be separated after the hydrogenation e.g. by filtration if the process is carried out batchwise.
  • Imines (II) can be prepared by reacting ketones (II) with a compound introducing the R N group, in particular with a primary amine, preferably methylamine.
  • the preparation of imines (II) is carried out in analogy to the method which is described in U.S. patent specification No. 4,536,518.
  • Nitrones (II) can be prepared by reacting ketones (II) with a compound introducing the R r N ⁇ 0 group, for example , -substituted hydroxylamine, preferably N-methylhydroxylamine.
  • the preparation of nitrones (II) is carried out in analogy to the method described in WO 98/27050.
  • Hydrogenation is carried out in the presence of an organic solvent. It is preferred to use non- polar or polar aprotic solvents or mixtures thereof.
  • non-polar solvents examples include hydrocarbons, for example aliphatic hydrocarbons, such as hexane, heptane or petroleum ether, cycloaliphatic hydrocarbons, such as cyclohexane or methylcyclohexane, aromatic hydrocarbons, such as benzene, toluene or xylene.
  • hydrocarbons for example aliphatic hydrocarbons, such as hexane, heptane or petroleum ether, cycloaliphatic hydrocarbons, such as cyclohexane or methylcyclohexane, aromatic hydrocarbons, such as benzene, toluene or xylene.
  • Suitable polar aprotic solvents are ethers, such as aliphatic ethers, e.g. 1 ,2- diethoxyethane or tert-butylmethyl ether, cyclic ethers, e.g. tetrahydrofuran or dioxan, amides, e.g. dimethylformamide or N-methylpyrrolidone. Ethers are particularly suitable, especially tetrahydrofuran.
  • acid assistants are added where required, for example organic mono- or polyvalent acids containing more than two carbon atoms, for example acetic acid, propionic acid or malonic acid, mineral acids such as sulfuric acid, so-called Lewis acids, such as boron trifluoride, or so-called solid acids, such as zeolites or National® and/or dehydrating agent, such as sodium sulfate.
  • organic mono- or polyvalent acids containing more than two carbon atoms for example acetic acid, propionic acid or malonic acid, mineral acids such as sulfuric acid, so-called Lewis acids, such as boron trifluoride, or so-called solid acids, such as zeolites or National® and/or dehydrating agent, such as sodium sulfate.
  • organic mono- or polyvalent acids containing more than two carbon atoms for example acetic acid, propionic acid or malonic acid, mineral acids such as sulfuric acid, so-called Lewis acids, such as boron trifluoride, or so-called solid
  • the process can be carried out in both variants preferably in the liquid phase batchwise or continuously, preferably with a catalyst suspension as liquid-phase hydrogenation or in a bubble column or with a formated catalyst in a trickle bed.
  • the reaction can also be carried out in the gas phase with a powdered catalyst in a fluidised bed or with a formulated catalyst in a fixed bed.
  • the hydrogenation can be carried out in a wide range of temperatures. Temperatures in the range from 60° to about 250 °C, preferably from 90° to 150°C, have been found to be advantageous.
  • the hydrogen pressure can vary within a wide range during hydrogenation, for example from 1 - 100, preferably from 5 - 50, more preferably from 10 - 20 bar. Which hydrogen pressure is used depends essentially on the hydrogenation plant available. At higher temperatures of about 100°C, molecular hydrogen can also be replaced by a hydrogen-donor, such as iso- propanol.
  • the reaction time can vary within wide limits. It depends on the catalyst used, on the hydrogen pressure, on the reaction temperature and on the plant used and can be, for example, from half an hour to 24 hours. Advantageous reaction times are those from about half an hour to 2 hours.
  • the isolation of the reaction products is carried out by known methods and is illustrated in the Examples. After separation of the catalyst and removal of the solvent, the conventional separation processes may follow, for example preparative thin-layer chromatography, preparative HPLC, preparative gas chromatography etc..
  • the cis-racemate obtained starting from racemic cyclohexylidenamine can be separated into the optically pure antipodes without any further purification using the known processes for enantiomer separation, for example by means of preparative chromatography on chiral substrates (HPLC) or by precipitation or crystallisation using optically pure precipitants, for example D -(-) or L -(-)-mandelic acid or (+) or (-)-IO-camphorsulfonic acid.
  • the enantiomer-pure 4-substituted cyclohexylamine is obtained directly by the hydrogenation process of this invention.
  • This invention also relates to the use of copper-containing catalysts for the diastereoselec- tive hydrogenation of cyclohexylidenamines.
  • copper chromite catalysts or CuZnAI-oxide catalysts for the diastereoselective hydrogenation of cyclohexylidenamines.
  • 0.1 g of barium-doped copper chromite catalyst (commercial product of S ⁇ dchemie, Girdler G 13, comprising 29% of Cu, 26% of Cr and 13.6% of Ba) and 40 ml of THF are placed in a 100 ml autoclave (stainless steel 316SS).
  • the catalyst suspension is prehydrogenated for 1 hour at 12 bar initial pressure H 2 at 130°C.
  • the suspension is then cooled and 0.5 g of 4-(3,4-dichlorophenyl)-1-methylimino-1 ,2,3,4-tetrahydronaphthalene is added.
  • hydrogenation is carried out for 18 hours at 100°C and 12 bar initial pressure H 2 (maximum pressure: 15 bar).
  • the catalyst is removed by filtration and the product is concentrated by evaporation under vacuum and dried under high vacuum.
  • the cis/trans ratio of the resulting 4-(3,4-dichlorophenyl)-1 ,2,3,4-tetrahydro-N-methyl-1 -naph- thylamine is > 95 : 5.
  • the crude product is purified via FLASH chromatography over silica gel at a solvent gradient of CH 2 CI 2 to CH 2 CI 2 /MeOH (9 : 1 ). This gives 83 % of the theoretical yield of pure cis-racemate.
  • the cis/trans ratio of the resultant 4-(3,4-dichlorophenyl)-1 ,2,3,4-tetrahydro-N-methyl-1-napthylamine is > 9 : 1.
  • the crude product is purified via FLASH chromatography over silica gel at a solvent gradient of CH 2 CI 2 to CH 2 CI 2 /MeOH (9 : 1 ). This gives 50 % of the theoretical yield of pure cis-racemate.
  • the resultant 4-(3,4-dichlorophenyl)-1 ,2,3,4-tetrahydro-N-methyl-1 -napthylamine is determined via HPLC: 97.3 to 2J. 20ml of a HCI-saturated THF solution are then added dropwise at 0°C to the solution of crude product. The corresponding crystalline hydrochloride precipitates and is collected by filtration over a glass suction filter and dried under vacuum. This gives 85% of the theoretical yield of pure cis-racemate. The melting point is 292-293°C after recrystallisation from absolute methanol.
  • catalyst commercial product of Engelhard Cu-0890 P, comprising 35% of CuO, 42% of ZnO and 21% of Al 2 0 3
  • 30 ml of THF and 3 g of 4-(3,4-dichlorophenyl)-1-methyl- imino-1 ,2,3,4-tetrahydronaphthalene are placed in a 100 ml autoclave (stainless steel 316SS). Hydrogenation is then carried out for 1 1 / 2 hours at 150°C and at 10 bar initial pressure H 2 (maximum pressure: 15 bar).
  • the catalyst is removed by filtration over Hyflo® and 0.1 ml of the solution is concentrated by evaporation under vacuum.
  • the sample is taken up in isopropanol and the cis/trans ratio of the resultant 4-(3,4-dichlorophenyl)-1 ,2,3,4-tetra- hydro-N-methyl-1-napthylamine is determined via HPLC: 99.0 : 1.0.
  • 1.5 g of D-(-)-mandelic acid are added to the solution of crude product and the solvent is stripped off, with heating, in a rotary evaporator. After drying for 12 hours under high vacuum, 100 ml of ethanol are added and the corresponding crystalline mandelate is dissolved under reflux conditions. After heating for 20 minutes the solution is cooled and stored overnight at room temperature.
  • the colourless crystals are filtered over a glass suction filter and the mother liquor is concentrated to half its volume and, after brief heating, cooled to the second crystallisation. This gives a further product fraction.
  • the total yield is 82% of theory.
  • the melting points are 191 °C and 190°C for the first and second fraction, respectively.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PCT/EP1999/001696 1998-03-18 1999-03-16 Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines Ceased WO1999047486A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE69916593T DE69916593T2 (de) 1998-03-18 1999-03-16 Verfahren zur cis-selektiven katalytischen hydrierung von cyclohexylidenaminen
EP99915616A EP1064250B1 (en) 1998-03-18 1999-03-16 Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
US09/646,211 US6232501B1 (en) 1998-03-18 1999-03-16 Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
IL13817299A IL138172A0 (en) 1998-03-18 1999-03-16 Process for the cis-selective hydrogenation of cyclohexylidenamines
JP2000536684A JP2002506844A (ja) 1998-03-18 1999-03-16 シクロヘキシリデンアミンのcis−選択的接触水素化方法
CA002323629A CA2323629A1 (en) 1998-03-18 1999-03-16 Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
AU34128/99A AU759530B2 (en) 1998-03-18 1999-03-16 Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
IL138172A IL138172A (en) 1998-03-18 2000-08-30 Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH64598 1998-03-18
CH645/98 1998-03-18

Publications (1)

Publication Number Publication Date
WO1999047486A1 true WO1999047486A1 (en) 1999-09-23

Family

ID=4191841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/001696 Ceased WO1999047486A1 (en) 1998-03-18 1999-03-16 Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines

Country Status (16)

Country Link
US (1) US6232501B1 (https=)
EP (1) EP1064250B1 (https=)
JP (1) JP2002506844A (https=)
CN (1) CN1216033C (https=)
AR (1) AR018164A1 (https=)
AU (1) AU759530B2 (https=)
CA (1) CA2323629A1 (https=)
DE (1) DE69916593T2 (https=)
ES (1) ES2217748T3 (https=)
HU (1) HUP0101322A3 (https=)
IL (2) IL138172A0 (https=)
PT (1) PT1064250E (https=)
TR (1) TR200002673T2 (https=)
TW (1) TWI220427B (https=)
WO (1) WO1999047486A1 (https=)
ZA (1) ZA200004624B (https=)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009080A1 (en) * 1999-07-29 2001-02-08 Ciba Specialty Chemicals Holding Inc. Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
WO2001036378A1 (en) * 1999-11-16 2001-05-25 Ciba Specialty Chemicals Holding Inc. Process for the preparation of ketimines
WO2001036377A1 (en) * 1999-11-16 2001-05-25 Ciba Specialty Chemicals Holding Inc. Process for the preparation of ketimines
US6452054B2 (en) 1999-12-21 2002-09-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
US6552227B2 (en) 2000-03-14 2003-04-22 Teva Pharmaceutical Industries Ltd. Process for preparing (+)-cis-sertraline
US6600073B1 (en) 1999-11-24 2003-07-29 Teva Pharmaceutical Industries Ltd. Methods for preparation of sertraline hydrochloride polymorphs
US6723878B2 (en) 2001-06-15 2004-04-20 Orion Corporation Fermion Method for preparing sertraline
US6897340B2 (en) 2002-04-29 2005-05-24 Teva Pharmaceutical Industries Ltd. Processes for preparation of polymorphic form II of sertraline hydrochloride
WO2004092110A3 (en) * 2003-04-14 2005-06-09 Teva Pharma Hydrogenation of imine intermediates of sertraline with catalysts
US6939992B2 (en) 1999-10-29 2005-09-06 Ciba Specialty Chemicals Corporation Polymorphic forms of sertraline hydrochloride
US7442838B2 (en) 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006129324A2 (en) 2005-06-03 2006-12-07 Hetero Drugs Limited A highly stereoselective synthesis of sertraline
US8354558B2 (en) * 2007-12-21 2013-01-15 Basf Se Process for diastereoselective conversion of chiral imines
US8415500B2 (en) * 2007-12-21 2013-04-09 Basf Se One-stage reductive amination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
WO1993001161A1 (en) * 1991-07-11 1993-01-21 Pfizer Limited Process for preparing sertraline intermediates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290806A (en) * 1990-03-06 1994-03-01 Basf Aktiengesellschaft 4-(4-tert-butylphenyl) cyclohexylamines, and fungicides containing same
IL112569A (en) * 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
HU222341B1 (hu) 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
DE19812054A1 (de) * 1998-03-19 1999-09-23 Hoechst Schering Agrevo Gmbh Verfahren zur Herstellung 4-substituierter cis-Cyclohexylamine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
WO1993001161A1 (en) * 1991-07-11 1993-01-21 Pfizer Limited Process for preparing sertraline intermediates

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900355B2 (en) 1999-07-29 2005-05-31 Ciba Specialty Chemicals Corporation Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
WO2001009080A1 (en) * 1999-07-29 2001-02-08 Ciba Specialty Chemicals Holding Inc. Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
US6720454B1 (en) 1999-07-29 2004-04-13 Ciba Specialty Chemicals Corporation Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
US7196222B2 (en) 1999-08-09 2007-03-27 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form II and methods for the preparation thereof
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
US7319171B2 (en) 1999-08-09 2008-01-15 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form II and methods for the preparation thereof
US6939992B2 (en) 1999-10-29 2005-09-06 Ciba Specialty Chemicals Corporation Polymorphic forms of sertraline hydrochloride
US7442838B2 (en) 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
WO2001036378A1 (en) * 1999-11-16 2001-05-25 Ciba Specialty Chemicals Holding Inc. Process for the preparation of ketimines
WO2001036377A1 (en) * 1999-11-16 2001-05-25 Ciba Specialty Chemicals Holding Inc. Process for the preparation of ketimines
US6693218B1 (en) 1999-11-16 2004-02-17 Ciba Specialty Chemicals Corporation Process for the preparation of ketimines
US6806386B1 (en) 1999-11-16 2004-10-19 Ciba Specialty Chemicals Corporation Process for the preparation of ketimines
US6600073B1 (en) 1999-11-24 2003-07-29 Teva Pharmaceutical Industries Ltd. Methods for preparation of sertraline hydrochloride polymorphs
US6858652B2 (en) 1999-12-21 2005-02-22 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
US6452054B2 (en) 1999-12-21 2002-09-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
US6552227B2 (en) 2000-03-14 2003-04-22 Teva Pharmaceutical Industries Ltd. Process for preparing (+)-cis-sertraline
EP1268369A4 (en) * 2000-03-14 2005-09-21 Teva Pharma NEW PROCESS FOR THE PREPARATION OF (+) - CIS-SERTRALINE
US6809221B2 (en) 2000-03-14 2004-10-26 Teva Pharmaceutical Industries Ltd. Process for preparing (+)-cis-sertraline
US6723878B2 (en) 2001-06-15 2004-04-20 Orion Corporation Fermion Method for preparing sertraline
US6897340B2 (en) 2002-04-29 2005-05-24 Teva Pharmaceutical Industries Ltd. Processes for preparation of polymorphic form II of sertraline hydrochloride
WO2004092110A3 (en) * 2003-04-14 2005-06-09 Teva Pharma Hydrogenation of imine intermediates of sertraline with catalysts
US7276629B2 (en) 2003-04-14 2007-10-02 Teva Pharmaceutical Industries Ltd. Hydrogenation of imine intermediates of sertraline with catalysts

Also Published As

Publication number Publication date
IL138172A (en) 2007-09-20
ES2217748T3 (es) 2004-11-01
DE69916593D1 (de) 2004-05-27
EP1064250A1 (en) 2001-01-03
HUP0101322A2 (hu) 2002-05-29
CN1216033C (zh) 2005-08-24
CA2323629A1 (en) 1999-09-23
US6232501B1 (en) 2001-05-15
DE69916593T2 (de) 2005-05-25
TR200002673T2 (tr) 2000-11-21
AU3412899A (en) 1999-10-11
AR018164A1 (es) 2001-10-31
EP1064250B1 (en) 2004-04-21
IL138172A0 (en) 2001-10-31
AU759530B2 (en) 2003-04-17
TWI220427B (en) 2004-08-21
ZA200004624B (en) 2001-11-29
HUP0101322A3 (en) 2002-06-28
JP2002506844A (ja) 2002-03-05
PT1064250E (pt) 2004-09-30
CN1293653A (zh) 2001-05-02

Similar Documents

Publication Publication Date Title
EP1064250B1 (en) Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
CA2734971C (en) Process for preparing cinacalcet
RU2181358C2 (ru) Способ получения сертралина из хирального тетралона
US6720454B1 (en) Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
CA1294612C (en) Process for the synthesis of 1-substituted imidazole-5-carboxylic acids and carboxylic acid derivatives
MXPA00008768A (en) Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
EP2036881B1 (en) Method for producing optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy-substituted phenyl)alkylamine n-monoalkyl derivative
EP1778620A1 (en) Process for the preparation of a diastereomerically enriched compound
CA2379217A1 (en) Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
EP1503978A1 (en) Process for the manufacture of sertraline
EP0916656A2 (en) A method for production of pyrrolidinone derivatives
CN120058609A (zh) 一种(r)-5-环戊基吡唑烷-3-酮的药用盐及其制备方法和用途
US5091526A (en) Process for the enantiospecific synthesis of intermediates for hexahydro-benzo[d]-naphtho[2,1-b]azepines
JP4896539B2 (ja) 3−アルキル−4,4’−ビフェノールの製造方法及び3−アルキル−4,4’−ビフェノールと3,3’−ジアルキル−4,4’−ビフェノールとの混合物の製造方法
MXPA00003689A (en) Process for the preparation of 1,1,1-trifluoro-2-aminoalkanes
CZ20002085A3 (cs) Způsob přípravy sertralinu z chirálního tetralonu
HK1029981A (en) Process for preparing sertraline from chiral tetralone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99804137.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999915616

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 138172

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 34128/99

Country of ref document: AU

Ref document number: 200004624

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/008768

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2323629

Country of ref document: CA

Ref document number: 2323629

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09646211

Country of ref document: US

Ref document number: 2000/02673

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/392/CHE

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999915616

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 34128/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999915616

Country of ref document: EP